Key Takeaways
- Core business delivered without Lenalidomide: With minimal US Lenalidomide profit share and deferred Glatiramer API sales, the base business still produced a strong quarter, proving the earnings power outside the blockbuster.
- CTPR is the near-term earnings catalyst: The newly launched agrochemical product had zero sales in Q2, but management expects it to drive a "good bump in earnings" starting Q3, with the peak in the June quarter.
- Subsidiaries now contribute nearly half of profitability: Brazil and Canada performed extremely well on new launches and one-off orders, and the combined business is expected to grow 50%+ in the next two quarters.
- US strategy bets on a handful of mega products: Management believes it needs "another three, four products like Revlimid in the next decade" and has filed two ANDAs it believes are first-to-file, with a pipeline of Carfilzomib, Losanta, Trabectedin, and Idelalisib playing out soon.
- What to watch next quarter: The ramp of CTPR sales in the domestic market, the double-bench court ruling on CTPR, FTF confirmation on the two recent US ANDA filings, and any announcement on the small domestic acquisition.
CTPR: The New Earnings Driver
- Zero to meaningful in one quarter: CTPR contributed no revenue in Q2, but management expects sales to begin in the December quarter, scale through March, and peak in the June kharif season, driving base business earnings for at least the next few quarters.
- Market share ambition: The internal target is a minimum 10–20% share of a market described as "so large" there is "enough money for everyone" for at least the next few quarters, with only one competitor currently present and perhaps two more expected.
- Inventory build underway: The company has enough stock for the upcoming rabi season and is now building inventory for kharif, because current levels will not be adequate for the peak season.
- Export opportunity is secondary for now: The team is working on export registrations in parallel, but registrations take time outside India, so the near-term story is entirely domestic.
- Legal overhang: The single-bench court order was won; the opposing party challenged it before a double bench, and the order is now reserved. Management believes "very strongly" the single-bench order will be upheld.
Rajeev Nannapaneni: "I'm very excited and I think you'll see a good bump in earnings in the next two quarters from CTPR, that will drive our base business in the next few quarters."
Lenalidomide: The Known Unknown
- Q2 was the trough: Profit share from US Lenalidomide exports was minimal in Q2, consistent with prior communication that this quarter would be lean.
- Q3 stays lean, then the floodgates reopen: Management expects Q3 contribution to remain minimal, with fresh quantity and the associated profit share arriving in Q4 and Q1 of next year, which will be "extremely full" like the previous Q4 and Q1.
- The annual reset cycle: Volume expansion is tied to a cycle that resets around March 1 each year, based on information from partner Teva, making Q4 and Q1 structurally the largest Lenalidomide quarters.
- Australia launch imminent: Lenalidomide has been launched in Australia through a partner as part of the first wave of generics alongside Sandoz, with a fixed launch date that cannot be disclosed due to confidentiality.
Rajesh Chebiyam: "I think considering the nature of our business and the way we do things; I think you have to take a 12-month earnings."
Subsidiaries: The Silent Profit Engine
- Nearly half of profitability now comes from subsidiaries: Brazil and Canada have done "extremely well," driven by new launches including Apixaban in both markets and some one-time tender and government orders.
- Growth trajectory is steep: The combined Canada and Brazil business, currently at about ₹0.9–1.0 crore, is expected to rise to ₹1.5 crore in the next two quarters.
- Pipeline supports the run: Revlimid is a big product in Canada; Brazil is driven by Everolimus and other products. Additional launches are expected "in the next few quarters," with announcements to follow as they happen.
- Globalization as a stability play: Management explicitly frames the push into multiple territories and countries as a strategy to bring more stability to earnings, reducing dependence on any single market or product cycle.
US Pipeline: Betting on Blockbusters
- The strategy is concentrated, not scattered: Management believes the US generics business requires delivering "three, four very large FTF type of products or complex generic type of products" to be competitive, because common products carry "less value."
- Two recent ANDA filings are the near-term catalysts: Both are believed to be interesting first-to-file products, subject to confirmation upon ANDA acceptance, which typically takes 60–90 days, meaning news is expected "in the next few weeks."
- The next wave of known products: Carfilzomib (Kyprolis) with first-to-file on one channel and "shade first-to-file" on the biggest strength, plus Losanta, Trabectedin, and Idelalisib, will "play out in the next few days."
- Generic Pomalyst is locked and loaded: Full US approval is in hand with a settlement and a launch date approximately two years from now, though the exact date is confidential.
Rajesh Chebiyam: "I still believe that we need to deliver at least three, four very large FTF type of products or complex generic type of products to be competitive in the US. ... if we're able to deliver another three, four products like Revlimid in the next decade, I think your whole decade is set."
Domestic Pharma: Steady, With Acquisition Ambition
- Oncology is stable: The domestic oncology business is described as "doing reasonably well" with no significant pricing pressure, though growth is constrained by the specialty-only sales force.
- The coverage gap is the binding constraint: The company only covers specialty doctors and does not reach general physicians or larger doctor segments, a gap management wants to close either by expanding the field force or through acquisition.
- Small acquisition is close: The company is hoping to close a transaction in the next few months, targeting a smaller asset with around ₹100–150 crores in sales, using a "brick-by-brick" approach to enter new therapeutic segments and gain access to doctors and stockists.
- A large acquisition is the ambition, not the plan: Management is also looking at a very large acquisition to build scale and double revenues, but acknowledges "these are not easy acquisitions to do, and they won't happen overnight."
- Eltrombopag verdict pending: A court verdict is awaited at the Delhi High Court; if cleared, it will be "a very good addition" to the domestic portfolio.
Rajeev Nannapaneni: "I think the challenge that we have is, we only cover specialty doctors, we don't cover general physicians and larger segments of doctors. So, I think that's what I believe in either we do it through increase of field force, or we do it through an acquisition."
Agro Sciences: Beyond CTPR
- CTPR is the first of a pipeline: Five to seven products are in the agro pipeline, with filings to be completed in the next few months, and other products similar to CTPR are described as "interesting" and expected to "bring value."
- The strategy is science-driven: The agro division targets products based on interesting science or patent litigation opportunities, and is also focusing on molecules with unique first-time applications.
- Capacity is ready: A separate manufacturing facility in Andhra Pradesh for agro technicals and formulations is operational, with enough capacity in both filling and technical lines to service 20–25% market share, and the plant is multi-product capable.
- Innovator alliances are off the table: Management was asked about partnering with innovators and deflected, stating that an "independent aggressive generic company" cannot do innovator alliances because "you can't have it both ways."
Rajesh Chebiyam: "When you're in a very aggressive generic company, you can't do innovator alliances, you can't have it both ways, you can't say that I will go up to your patent, but I will also supply product to you, it doesn't work like that. You have to choose one camp."
Guidance & Commitments
| Commitment | Specifics | Timeline |
|---|---|---|
| CTPR sales ramp | Sales begin and drive base business earnings | Starting Q3 FY23 (December quarter), peak in Q1 FY24 (June quarter) |
| Lenalidomide US profit share | Minimal in Q3; fresh quantity and full profit share resume | Q4 FY23 and Q1 FY24 |
| Subsidiary revenue growth | Canada + Brazil combined business to rise from ₹0.9–1.0 cr to ₹1.5 cr | Next two quarters |
| US ANDA FTF confirmation | FTF status on two recent filings to be known upon ANDA acceptance | Next few weeks (acceptance takes 60–90 days) |
| Generic Pomalyst US launch | Launch per settlement terms | Approximately two years from now |
| Small domestic acquisition | Close a transaction for an asset with ~₹100–150 cr in sales | Next few months |
| Lenalidomide volume expansion | Annual reset cycle adds volume | Around March 1 each year |
| CTPR double-bench ruling | Verdict on the appeal against the single-bench order | Order reserved; timeline unspecified |
Key Metrics
| Metric | Q2 FY23 |
|---|---|
| Consolidated total revenue | ₹452.6 cr, approximately 9% growth YoY from ₹415.2 cr |
| Consolidated net profit | ₹56.8 cr, against ₹65.1 cr in same period last year |
| Lenalidomide US export profit share | Minimal, as communicated in prior calls |
| Oncology domestic sale | ₹55 cr |
| Canada subsidiary revenue (last quarter) | ₹0.65 cr |
| Brazil subsidiary revenue (last quarter) | a little less than ₹0.3 cr |
| Canada and Brazil combined business | ₹0.9 to 1 cr, expected to increase to ₹1.5 cr in next two quarters |
| Standalone inventory | ₹665 cr as of 30th September 2022, of which ₹110 cr is agro inventory |
| Cash and cash equivalents | ₹1,000 cr as of end of Q2 |
| Borrowings | ₹82 cr, of which ₹50 cr is foreign bill discount associate |
| CTPR molecule market size (plain plus combination) | a little less than ₹3,000 cr (₹2,000 cr plain, ₹800 cr combination) |
| CTPR expected revenue split | 50% to 60% or more from B2B, about 35% to 40% from B2C |
| CTPR discount on MRP | about 25%, plus additional trade discounts |
| Domestic business acquisition target size | ₹100-150 cr worth of sale |
| Dividend payout plan | about 20% to 25% of cash flow |